Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study-Reference-Cited by-同舟云学术

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Published:2019-04 Issue:10182 Volume:393 Page:1699-1707
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ye Byong Duk,Pesegova Marina,Alexeeva Olga,Osipenko Marina,Lahat Adi,Dorofeyev Andriy,Fishman Sigal,Levchenko Olena,Cheon Jae Hee,Scribano Maria Lia,Mateescu Radu-Bogdan,Lee Kang-Moon,Eun Chang Soo,Lee Sang Joon,Lee Sung Young,Kim HoUng,Schreiber Stefan,Fowler Heather,Cheung Raymond,Kim Young-Ho

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Crohn's disease;Baumgart;Lancet,2012

2. Long-term evolution of disease behavior of Crohn's disease;Cosnes;Inflamm Bowel Dis,2002

3. Current and emerging therapeutic targets for IBD;Neurath;Nat Rev Gastroenterol Hepatol,2017

4. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management;Gomollon;J Crohns Colitis,2017

5. How expensive is inflammatory bowel disease? A critical analysis;Odes;World J Gastroenterol,2008

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease;Arab Journal of Gastroenterology;2024-08

3. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

4. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01

5. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24